Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equity interest in CWE European Holdings Inc. ("CWE") not already owned by the Company, through a series of ancillary transa
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-12 7:30 AM EDT | Neural Therapeutics Inc.
Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) (the "Company" or "Britannia") is pleased to announce that it has completed a strategic investment of approximately $5.3 million in a portfolio of performing commercial equipment loans (the "Investment") on highly opportunistic terms. The Investment represents the continued execution of the Company's asset-backed lending strategy and meaningfully expands the Company's base of recurring, high-return c
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2026-06-12 7:30 AM EDT | Britannia Life Sciences Inc
Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., has officially launched a targeted market test and comprehensive product trial across the Commonwealth of The Bahamas. The pilot program is being executed in direct partnership with a premier mobile-first delivery application, digital logistics, and
Technology, Biotechnology, Health
2026-06-10 8:00 AM EDT | Restart Life Sciences Corp.
CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company's news release dated June 9, 2026. The appointment of Mr. Emes to the Company's Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated. All other information contained in th
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-06-09 7:32 PM EDT | Entheon Biomedical Corp.
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-09 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Entheon Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes to the Company's Board of Directors, effective April 3, 2025. Mr. Emes is a seasoned entrepreneur with extensive experience in capital markets, corporate development and investor relations. He is the Co-Founder of Black Swan Solutions Inc., where he has worked with over 80 clients
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-06-09 4:26 PM EDT | Entheon Biomedical Corp.
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Patent Allowance for Application No. 18/304,741, titled "Method of Detecting Lung Cancer." The allowed patent covers the proprietary use of ur
Technology, Biotechnology, Healthcare and Hospitals
2026-06-09 8:30 AM EDT | BioMark Diagnostics, Inc.
Dr. Christina Rahm and The ROOT Brands Celebrate Dual Gold Stevie(R) Awards in New York City
New York, New York--(Newsfile Corp. - June 8, 2026) - Dr. Christina Rahm and The ROOT Brands are celebrating a milestone moment as company leadership gathers in New York City for the 24th Annual American Business Awards®, where both the organization and its founder, Dr. Christina Rahm, have been recognized with prestigious Gold Stevie® Awards for innovation, manufacturing excellence and scientific leadership. The national recognition highlights the contin
Biotechnology, Food / Beverages, Health
2026-06-08 5:57 PM EDT | DRC Ventures
Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
Burlington, Massachusetts--(Newsfile Corp. - June 8, 2026) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, the Company's novel subcutaneously (SC) administered ADC delivering a potent glucocorticoid (GC) directly to immune cells. Phase 1 data from healthy participants (HPs) presented at EULAR 2026 (European
2026-06-08 8:31 AM EDT | Lifordi
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchisi
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-08 7:00 AM EDT | Cannabis Bioscience International Holdings
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and Australia Patent pending pharmacodynamic response biomarker accepted as surrogate clinical efficacy endpoint TGA and MHRA agree to allow utilization of remaining Phase 2b drug product for initiation of confirmatory Phase 3 FDA and EMA fully align with Company on Chemistry, Manufacturing and Con
2026-06-08 6:00 AM EDT | OS Therapies
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effectiv
Biotechnology, Pharmaceuticals, Health
2026-06-08 3:00 AM EDT | PreveCeutical Medical Inc.
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq. As previously di
Biotechnology, Pharmaceuticals
2026-06-04 5:00 PM EDT | InMed Pharmaceuticals
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026 Dates: June 16-18, 2026 Location: Bellagio Hotel & Ca
Biotechnology, Healthcare and Hospitals
2026-06-04 8:30 AM EDT | Envoy Medical, Inc.
TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally
Highlights TempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent protecting th
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Lists Warrants on the TSXV
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share p
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-06-03 7:00 AM EDT | Theralase Technologies Inc.
Restart Life Sciences Appoints Inez Ho as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the appointment of Inez Ho as Chief Financial Officer (CFO) of the Company, effective immediately. Ms. Ho brings over 12 years of robust finance and accounting experience to Restart Life, with a strong track record of supporting publicly listed companies across diverse industries. Her deep areas of e
Technology, Biotechnology, Health
2026-06-03 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations. Dr. Beaver has held senior leadership position
Biotechnology, Pharmaceuticals, Health
2026-06-03 3:15 AM EDT | Defence Therapeutics Inc.
iOrganBio Appoints Zhiping Pang, M.D., Ph.D., to Scientific Advisory Board
Chapel Hill, North Carolina--(Newsfile Corp. - June 2, 2026) - iOrganBio, an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs), today announced the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is one of the leading experts in human neuron biology, synaptic function,
2026-06-02 8:39 AM EDT | iOrganBio
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034) Updated clinical efficacy data being added to regulatory dossiers as Company seeks early market authorizations in U.S., U.K., Europe and Australia in 2nd half of 2026 EMA and Australia TGA (TGA) alignment achieved on early Q4-202
2026-06-02 6:00 AM EDT | OS Therapies